The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA 2019 |The role of iNKT cells in CAR immunotherapy and acute graft-versus-host disease prophylaxis

Jul 4, 2019

At the 24th European Hematology Association (EHA)Congress in Amsterdam, Professor Anastasios Karadimitrisfrom Imperial College London, London, United Kingdom, gave a presentation about invariant NKT (iNKT)-cellson Saturday, June 16. iNKT-cells control a variety of immune responses with the enhancement of anti-tumor and anti-pathogen responses, as well as protection from auto-immunity and allo-reactivity, especially in acute graft-versus-host disease (aGvHD). 1

iNKT-cells are a rare type of T cells (a subset of TCRab T cells with patterns of adaptive and innate immune responses) and represent <0.1% of cells in the blood, with the ability to migrate and home into different tissues. These cells are controlled by non-polymorphic CD1d cells presenting a specific glycolipid HLA class I-like molecule. It was hypothesized that iNKTcells received from third-party donors would offer an ‘off-the-shelf’ treatment option for aGvHD. 2-4

iNKT-cells for CAR immunotherapy

  • In the last couple of years, chimeric antigen receptor (CAR)-T cell immunotherapy has been demonstrated to yield durable responses in patients with hematological malignancies
  • A single dose of 2 ndgeneration CAR19-iNKT-cells without in vivo cytokine support in comparison with CAR19-T cells shows superior anti-lymphoma effect in vivo through dual targeting of CD19 by CAR19 and of CD1d
  • V. administered CAR19-iNKT cells rapidly reduced the number of secondary central nervous system lymphoma cells due to higher expression of integrins by iNKT-cells in order to move across the blood-brain barrier
  • Upregulation of CD1d expression in lymphoma and CLL B-cells with all-trans retinoic acid leads to the augmentation of the anti-lymphoma effect of CAR19-iNKT-cells
  • The pre-clinical potential of CAR-iNKT-cells in other CD1d-expressing malignancies such as multiple myeloma should be further explored
  • The evaluation of CAR-iNKT-cells in the clinical setting is already underway

iNKT cells for aGvHD prophylaxis

  • aGvHD is mediated by allogeneic T-cells
  • Allo-iNKT-cells are not involved in aGvHD development, as a consequence, these cells would represent a promising platform for ‘off-the-shelf’ CAR immunotherapy without the necessity of TCR deletion
  • Previous studies have shown that donor iNKT cells may prevent aGvHD without increasing relapse rates 5
  • Pre-clinical and clinical data showed that donor iNKT cells are able to prevent aGvHD without increasing the risk of disease relapse: transfer of donor CD4+ iNKT cells in the presence of alpha-galactosylceramide, a glycolipid that selectively and powerfully stimulates iNKT-cells, prevents the development of experimental aGvHD in an HLA mismatched setting
  • Donor iNKT-cells were shown to be more than 10 times more effective than T regsfor aGvHD prophylaxis in mice without affecting the graft-versus-leukemia effect 6
  • Early posttransplant iNKT cell recovery can predict the occurrence of aGvHD and improved overall survival through a

Conclusions

  • Pre-clinical and clinical evidence supports a critical role of donor iNKT cells in protection from aGvHD
  • iNKT cells provide an optimal platform for chimeric antigen receptor-based immunotherapy of blood cancers
  • iNKT cell-based, ‘off-the-shelf’ immunotherapy could be sourced from allogeneic, healthy donors without risk of aGvHD
  1. Karadimitris A. Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute graft-versus-host disease. EHA 2019.
  2. Salio M. et al. Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol. 2014;32:323–366.
  3. Bendelac A. et al.The Biology of NKT Cells. Annu Rev Immunol. 2007;25:297–336.
  4. Tian G. et al. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016;126:2341–2355.
  5. Yang J. et al. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Transfusion. 2010;50:407–417.
  6. Leveson-Gower DB. et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood. 2011;117:3220–3229.
  7. Rubio MT. et al. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood. 2012;120:2144–2154.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox every month